Treatment of osteoporotic vertebral fractures by Laurent, Michaël
Copyright 2014 American Medical Association. All rights reserved.
induced tumor growth andmetastatic spread throughantian-
giogenic and immunostimulatory mechanisms.
Accumulatingclinical evidence suggests thatβ-ARantago-
nist, and propranolol in particular,may increase survival and
decrease recurrence in patientswith breast cancer.3 Barron et
al2 have studied the associations between use of β2-AR (pro-
pranolol)orβ1-selectiveantagonists (atenolol) andriskofbreast
cancer. They show that propranolol is associatedwith signifi-
cantly lessadvanceddiseaseatdiagnosisand lowersbreastcan-
cer-specific mortality. Furthermore, Pasquier et al3 strongly
suggest thatpropranololwith chemotherapymay improve the
outcome of women with breast cancer. In contrast, a recent
study foundno protective effect of propranolol (which repre-
sented 16%of the β-blockers prescribed) and increased recur-
rence rates associated with metoprolol.4
Propranolol is alsoanewandemerging treatment formela-
noma, multiple myeloma, pancreatic cancer, head and neck
squamous cell carcinoma cell lines, or severe infantile
haemangioma.5 Itwould thusbe interesting toevaluate the risk
of breast cancer according to the subtype of β-blockers and,
inparticular, nonselective β-blockers.Would it bepossible for
the authors of this article toprovidebreast cancer riskdata ac-
cording to the type of β-blockers?
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In ReplyWeappreciate the comments ofHugon-Rodin et al and
Ji andChenandrespondto the issues theyraised.Hugon-Rodin
et al raised the question of whether the relationship between
β-blocker use and breast cancer risk varied when results were
stratifiedaccordingtotypeofβ-blocker.Asreportedinourarticle,1
overallwefoundnorelationshipbetweencurrentuseorlong-term
currentuse (for≥10years)ofβ-blockersandriskof invasiveduc-
tal breast cancer (odds ratio [OR], 0.9 [95%CI, 0.7-1.2], andOR,
1.1[95%CI,0.7-1.8],respectively).Noappreciablevariationsinrisk
wereseenwhenweanalyzedrisksaccordingtocurrentuseofβ1-
selective blockers vs nonselective β-blockers. Specifically, cur-
rentusersofβ1-selectiveblockersofanydurationandfor10years
ormorehadORsof0.9 (95%CI,0.7-1.2) and1.2 (95%CI,0.7-1.9),
respectively,andcurrentusersofnonselectiveβ-blockersofany
durationandfor10yearsormorehadORsof0.8 (95%CI,0.4-1.6)
and0.8 (95%CI,0.3-2.4), respectively.However,90%ofcontrol
women who were current β-blocker users were users of a β1-
selectiveblocker (theother 10%werecurrentusersofnonselec-
tive β-blockers), limiting our power todetect differences in risk
between β1-selective blockers vs nonselective β-blockers.
Ji and Chen asked about the influence other potential con-
foundersmayhavehadonour risk estimates, specificallyheart
disease and duration of hypertension history. Adjustment for
heartdiseasedidnotappreciably influencethemagnitudeordi-
rectionof anyof the risk estimates reported inTable 2of our ar-
ticle. Specifically, in Table 2, the risk estimate associated with
currentuseofcalciumchannelblockers for10yearsormore(OR,
2.4 [95% CI, 1.2-4.9]) did not change after additional adjust-
ment forhistoryofheartdisease (OR,2.4 [95%CI, 1.2-5.0]).With
respect to duration of hypertension history, we defined this as
years between age at initial hypertension diagnosis and refer-
ence age. This variable is highly correlatedwith duration of an-
tihypertensiveuse,andthusweonlyassesseditspotentialtocon-
found current antihypertensiveuse risk estimates.Noneof our
current use risk estimates reported in Table 2were statistically
significant, andadditionaladjustment fordurationofhyperten-
sionhistorydidnotappreciablychange themagnitudeordirec-
tionofanyof theseestimates.Wedidnotcollect informationon
hypertension severity (howwell hypertensionwas controlled),
and our ascertainment of only self-reported dose information
limited our ability to evaluate dose-response relationships.
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Treatment of Osteoporotic Vertebral Fractures
To theEditorMcCulloughet al1 reported that apparentmortality
reductions following vertebroplasty and kyphoplasty likely re-
sult from selection bias. These findings are important to coun-
terhastyconclusionsfromseveralrecentpopulation-basedstud-
iesandreviews.Yetthesenewresultsarehardlysurprising,given
the a priori lack of evidence to assume a causal association be-
tweenvertebral fractures andmortality, let alonemortality risk
modifiable by targeting the spine. Reduced pulmonary func-
tion following vertebral fracture would be a plausible mecha-
nistic explanation,butonly small, short-term improvements in
vital capacity followingvertebralaugmentationhavebeendem-
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onstrated.Contrary to the frequentlycited increasedriskofpul-
monary deaths in older women with prevalent vertebral frac-
tures in the StudyofOsteoporotic Fractures, incident vertebral
fractures (arguably thestrongeroutcome) inthatcohortwereno
longerassociatedwithmortality followingadjustment forother
determinants such as frailty.2 The same authors have further
shown thathyperkyphosis andheight loss are equallyunfavor-
able, independentofvertebralfracturesandtheircharacteristics,3
arguing against a direct role of the latter.
On the other hand, the underlying osteoporosis, as well
as frailtyanddisability resulting fromfractures, areknownma-
jordirect causesof subsequentmortality, especially if thenext
fracture occurs at the hip. Moreover, not only population-
based studiesbut also several recent randomizedclinical trials
andmeta-analyses suggest thatwhile tremendousunderrecog-
nition and undertreatment of osteoporosis persists, treat-
mentofhigh-risk individualsprobablydoeshave indirectmor-
tality benefits.4 Thus, although it was omitted from the
discussion of McCullough et al1 and the accompanying In-
vited Commentary,5 it cannot be overemphasized that spinal
augmentation procedures are no substitute for appropriate
evaluation and treatment of underlying fracture risk.
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To the EditorWe read with interest the article by McCullough
et al.1 The authors have used the Medicare data set to per-
formamortality analysis and cited our study2 as being in con-
trast to their findings. Their study suggests that, because of
selection bias, our finding that vertebral augmentation had a
measurable and positive effect on mortality was incorrect.
However,we stand by our finding andnote several important
limitations of the study by McCullough et al.1
• Their preprocedure subgroup (augmentation >30 days after
vertebral compression fracture [VCF]) analysiswas flawed in
excluding most augmentation patients (71.3%). Essentially
they failed to consider the majority of augmentation pa-
tients,whomayhaveneededemergent care,whichcouldex-
plain why their treatment was within 30 days of VCF.
• McCullough et al1 stated that the augmentation group was
healthier (hence the selectionbias), but their owndata shows
a significantly lowerQuan comorbidity score and lower rates
of prior inpatient admissions as well as chronic pulmonary
disease for the control group,which is strongly suggestive of
improved health state in the control group.
• Theydidnot stratify the treatment groupby treatment type.
Because71%of theirpatientsunderwentvertebroplasty, their
treatment cohort would be biased.
• Theyonlyconsideredbaselinecomorbidities, ie, they failed to
account for conditions that led to the VCF. Furthermore they
consideredonly a limited set of comorbidities comparedwith
other similar studies that includedmore comorbidities.
• They failed toconsider that theiranalysis includedhealthcare
utilizationandmajormedical complicationsprior to theaug-
mentation for the treatment group, ie, unrelated to the pro-
cedure. This approach favors the control group.
Thus, while the data and results in the article by
McCullough et al1 may be accurate as stated, they do not ac-
curately represent or estimate the overall outcomes follow-
ing VCF in the entire Medicare population.
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In Reply We appreciate the comments of Edidin and col-
leagues as they touchonkey elements of our study,1 and their
previous article2 provides insightful contrast to our own.
We includedthe“preproceduresubgroup”analysis to illus-
tratethatasubstantialproportionoftheaugmentedgroup(29%)
hadamarkedly lower riskofcomplicationscomparedwithcon-
trolsdespitebeing“theoretically”equivalent—bothgroupshad
thesametreatmentduring this time (noaugmentation), andwe
controlledforbaselinecharacteristics, includingQuancomorbid-
ityscores,priorinpatientadmissions,andchronicpulmonarydis-
ease, amongothers,using traditionalmultivariatemodels.Edi-
dinetalareright tobeconcernedthat thesetraditionalmultivar-
iatemodelsmightnot adequatelyaccount for acutedifferences
inhealthat thetime,suchaspatientsneedingemergentcare.We
agree.Therearemanyotherclinicaldetailsavailable inreal-time
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thatarenotevident inbillingclaimsdata.Theentireclinicalpic-
ture at presentation, past andpresent,will influence therapeu-
ticdecisionsaswellaseventualpatientoutcomes.Wesuggestse-
lectionbias is theunmeasured factor allowing2“theoretically”
equivalent groups to have suchdifferent outcomes.
We did consider the possibility that clinicians may pref-
erentially perform spinal augmentation on the sickest pa-
tients so as to maximize their chances of survival—emergent
spinal augmentation, if you will. Complications should then
behighest immediatelybefore theprocedure, aspatients clini-
cally declare their need formore aggressive care. As Figure 2B
in our article illustrates, however, preprocedure complica-
tions were less than postprocedure complications.1 In fact,
therewasanadir in complications immediatelybefore thepro-
cedure and a spike immediately after the procedure. We in-
terpret these results to indicate that the majority of patients
arenotundergoingaugmentationbecauseofdireclinicalneed.
Severalmethodological clarificationsmaybehelpful.First,
we did not stratify by treatment type (vertebroplasty vs ky-
phoplasty) in our analysis.However,wehave compared these
2 treatments using these data and found no benefit of kypho-
plasty over vertebroplasty. A recent randomized clinical trial
comparing vertebroplasty with kyphoplasty also did not find
benefit of one over the other.3 Second, we collected “base-
line” comorbid conditions over the entire year prior to frac-
ture. We included osteoporosis in that list, presumably the
cause of the fracture. Unlike Edidin et al,2 we excluded all pa-
tients with diagnoses of cancer so as not tomix fractures due
tometastases with those due to osteoporosis. Third, we used
the date of fracture as baseline so that both groups would be
compared relative to the sameexposure (fracture) rather than
starting the comparisonwhen the augmentedgrouphad their
procedure, which could be as late as 6 months later.
Finally, Edidin et al failed to note in their letter that at the
timeof their articledemonstrating themortalitybenefitsof spi-
nal augmentation and, in particular, kyphoplasty, over conser-
vative therapy, Dr Edidin was an employee and stockowner of
Medtronic Inc, amanufacturer of kyphoplasty supplies.
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Actual Involvement vs Preference for Involvement
as an Indicator of SharedDecisionMaking
TotheEditorThearticlebyTakandcolleagues1abouttheassocia-
tionbetweenpatientpreferencesforshareddecisionmakingand
hospital resourceusetouchesonaverytimelytopic.ManyWest-
ernhealthcaresystemsarepreparing for thechallengesofaging
patients who are increasingly coping with the chronic conse-
quences of disease rather than acute disease itself.
Central inthistransitionisto(re)establishapatient-physician
partnershipbecause in themanysituationswhere“preference-
sensitive”decisions2aretobemade,unwarrantedpracticevaria-
tionislarge.3Shareddecisionmakingisexpectedtoresult inmore
satisfiedpatientswhoreceivecarebetteralignedwiththeirpref-
erences and in lower health care spending.4
ThestudybyTaketal1 adds to theevidencebasedatashow-
ingthathospitalpatients’preferencesforbeinginvolvedinmedi-
cal decisionmaking is related tohigher rather than lower costs,
an observation seemingly opposed to the aforementioned
hypothesis—or not? The authors related patient preferences for
their involvement in hospital resource use, not their actual
involvement. Although it is likely that patients whowant to be
involved aremore involved, the two are not the same. This ob-
servation is crucial for the interpretation of these results: for
individuals,patientpreference for involvementandtheiractual
involvementmayinfactbereverselyrelated,wherepreviousex-
periencesof too little involvementmay increasepreferences for
being involvedbut—givenunchangedphysicians’behaviors—at
the same time still result in low levels of actual involvement. In
addition,therelationsbetweenpatientpreference,actualinvolve-
ment,andresourceusemaybeconfoundedbysuchfactorsasdis-
ease severity, coping styles, orhopes for the future—factorsdif-
ficult toadjust for.Finally, this studywasperformed inanacute
care hospital setting, whereas a primary care settingmay have
beenmore appropriate to evaluate this research question. This
mayalsobereflectedinthefactthatmorethan70%ofthepatients
interviewedpreferred“to leavemedicaldecisionmakingtotheir
physicians.”
Shareddecisionmakingcanonlybeasuccessfulstrategyfor
cost containment and increasedpatient satisfaction, if patients
andhealthcareprofessionalsmutuallyagreeonshareddecision
makingasthebasisofhealthcareprovisionandcontinuouslyap-
ply it intheirongoingcommunicationaboutthebest-fittingcare.
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